AMTI News and Press, Applied Molecular Transport Inc. From 08/14/23

Currently Pursuing Strategic Alternatives, with MTS Health Partners, L.P. Advising the Company Cash and Cash Equivalents of $22.5 million, as of June 30, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT)...

2023-05-12 06:54:17 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q1 GAAP EPS of -$0.71. As of March 31, 2023, cash and cash equivalents were $41.8 million. The company believes its cash and cash equivalents will be sufficient to allow the company to ...

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2023. Recent Business Highlights Engaged MTS Health Partners, L.P....

2023-03-27 16:34:02 ET Applied Molecular Transport ( NASDAQ: AMTI ) is seeking strategic alternatives, and as part of a restructuring, has laid off ~57% of its workforce. The biopharma has hired MTS Health Partners as an advisor. Prior to the announcement after Monday'...

SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company’s board of directors approved a workforce reduction of approximately 57% of its employee base ...

2023-03-09 17:56:58 ET Applied Molecular Transport press release ( NASDAQ: AMTI ): Q4 GAAP EPS of -$0.58 beats by $0.01 . As of December 31, 2022, cash and cash equivalents were $61.1 million compared to $159.8 million for the year ended December 31, 2021. F...

Exploring strategic partnership options to advance AMT-101 for chronic pouchitis, an orphan indication with no FDA-approved products Evaluating next steps for the company's second clinical asset, AMT-126 SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Applied Mol...

New positive data demonstrate oral AMT-101’s gut-restricted profile with tissue-level pharmacodynamics (PD) effects and no systemic exposure by design Translational analysis reveals IL-10 biological responses in both 3mg and 10mg dose arms SOUTH SAN FRANCISCO, Calif., March...

Nano-cap biotech Applied Molecular Transport ( NASDAQ: AMTI ) lost ~16% pre-market Friday after JMP Securities downgraded it to Market Perform from Outperform, citing a setback for its Phase 2 trial for oral ulcerative colitis candidate AMT-101. On Thursday, the South San Fran...

AMT-101, an oral candidate for ulcerative colitis from Applied Molecular Transport ( NASDAQ: AMTI ), has failed in a phase 2 trial . Top-line data showed that that the clinical remission rate was higher in the placebo group than the treatment group. AMT-101 was given as a mono...